Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer

Current Pharmaceutical Biotechnology

Volumn 15, Issue 5, 2014, Pages 475-485

  Rolfo, Christian ^a   Bazan, Viviana ^b   Caruso, Stefano ^b   Cicero, Giuseppe ^b   Fanale, Daniele ^b   Russo, Antonio ^b   Hong, David S ^c   Piha Paul, Sarina A ^c   Tsimberidou, Apostolia M ^c   Pauwels, Patrick ^a   Van Meerbeeck, Jan P ^a   Giovannetti, Elisa ^d  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Lung cancer; microRNA; Oncogenic pathways; Resistance; Targeted agents

Indexed keywords

3 INDOLEMETHANOL; 3, 3' DIINDOLYLMETHANE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CURCUMIN; DOCETAXEL; EPIGALLOCATECHIN GALLATE; ERLOTINIB; ISOFLAVONE; MICRORNA; MICRORNA 100; MICRORNA 135A; MICRORNA 155; MICRORNA 181A; MICRORNA 181B; MICRORNA 192; MICRORNA 194; MICRORNA 200B; MICRORNA 21; MICRORNA 212; MICRORNA 337; MICRORNA 34C; MICRORNA 424; MICRORNA 451; MICRORNA 453; MICRORNA 497; MICRORNA 630; MICRORNA 98; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; BIOGENESIS; CANCER INCIDENCE; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CHEMOTHERAPY; DNA DAMAGE; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; METASTASIS; NEOPLASM; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL; UPREGULATION; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; MICRORNAS;

EID: 84907170770     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140519123219     Document Type: Article

References (109)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin., 2012, 62(1), 10-29.
2. Langer, C. J.; Besse, B.; Gualberto, A.; Brambilla, E.; Soria, J. C. The evolving role of histology in the management of advanced non-small-cell lung cancer. J. Clin. Oncol., 2010, 28(36), 5311-5320.
3. Giovannetti, E.; Erozenci, A.; Smit, J.; Danesi, R.; Peters, G. J. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit. Rev. Oncol. Hematol., 2012, 81(2), 103-22.
4. Ambudkar, S. V.; Dey, S.; Hrycyna, C. A.; Ramachandra, M.; Pastan, I.; Gottesman, M. M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 361-398.
5. Rodrigues, A. S.; Dinis, J.; Gromicho, M.; Martins, C.; Laires, A.; Rueff, J. Genomics and cancer drug resistance. Curr. Pharm. Biotechnol., 2012, 13(5), 651-673.
6. Longley, D. B.; Johnston, P. G. Molecular mechanisms of drug resistance. J. Pathol., 2005, 205(2), 275-92.
7. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2(1), 48-58.
8. Townsend, D. M.; Tew, K. D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene, 2003, 22(47), 7369-7375.
9. Johnston, P. G.; Drake, J. C.; Trepel, J.; Allegra, C. J. Immunological Quantitation of Thymidylate Synthase Using the Monoclonal-Antibody Ts 106 in 5-Fluorouracil-Sensitive and 5-Fluorouracil-Resistant Human Cancer Cell-Lines. Cancer Res., 1992, 52(16), 4306-4312.
10. Galvani, E.; Peters, G. J.; Giovannetti, E. EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity. Future Oncol., 2012, 8(8), 1015-1029.
11. Rosell, R.; Lord, R. V.; Taron, M.; Reguart, N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer, 2002, 38(3), 217-227.
12. Lord, R. V.; Brabender, J.; Gandara, D.; Alberola, V.; Camps, C.; Domine, M.; Cardenal, F.; Sanchez, J. M.; Gumerlock, P. H.; Taron, M.; Sanchez, J. J.; Danenberg, K. D.; Danenberg, P. V.; Rosell, R. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res., 2002, 8(7), 2286-2291.
13. Liu, A.; Yoshioka, K.; Salerno, V.; Hsieh, P. The mismatch repairmediated cell cycle checkpoint response to fluorodeoxyuridine. J. Cell Biochem., 2008, 105(1), 245-254.
14. Adhikari, S.; Choudhury, S.; Mitra, P. S.; Dubash, J. J.; Sajankila, S. P.; Roy, R. Targeting base excision repair for chemosensitization. Anticancer Agents Med. Chem., 2008, 8(4), 351-357.
15. Polischouk, A. G.; Holgersson, A.; Zong, D.; Stenerlow, B.; Karlsson, H. L.; Moller, L.; Viktorsson, K.; Lewensohn, R. The antipsychotic drug trifluoperazine inhibits DNA repair and sensitizes non small cell lung carcinoma cells to DNA doublestrand break induced cell death. Mol. Cancer Ther., 2007, 6(8), 2303-2309.
16. Hansen, L. T.; Lundin, C.; Spang-Thomsen, M.; Petersen, L. N.; Helleday, T. The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int. J. Cancer, 2003, 105(4), 472-429.
17. Bunz, F. Cell death and cancer therapy. Curr. Opin. Pharmacol., 2001, 1(4), 337-341.
18. Fojo, T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist. Updat., 2007, 10(1-2), 59-67.
19. Lagos-Quintana, M.; Rauhut, R.; Lendeckel, W.; Tuschl, T. Identification of novel genes coding for small expressed RNAs. Science, 2001, 294(5543), 853-858.
20. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004, 116(2), 281-297.
21. Lee, R. C.; Feinbaum, R. L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75(5), 843-54.
22. Corsini, L. R.; Bronte, G.; Terrasi, M.; Amodeo, V.; Fanale, D.; Fiorentino, E.; Cicero, G.; Bazan, V.; Russo, A. The role of microRNAs in cancer: Diagnostic and prognostic biomarkers and targets of therapies. Expert Opin. Ther. Targets, 2012, 16(Suppl 2), S103-109.
23. Caruso, S.; Bazan, V.; Rolfo, C.; Insalaco, L.; Fanale, D.; Bronte, G.; Corsini, L. R.; Rizzo, S.; Cicero, G.; Russo, A. MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? Oncogenesis, 2012, 1, e32.
24. Lee, Y.; Kim, M.; Han, J.; Yeom, K. H.; Lee, S.; Baek, S. H.; Kim, V. N. MicroRNA genes are transcribed by RNA polymerase II. EMBO J., 2004, 23(20), 4051-4060.
25. Borchert, G. M.; Lanier, W.; Davidson, B. L. RNA polymerase III transcribes human microRNAs. Nat. Struct. Mol. Biol., 2006, 13(12), 1097-1101.
26. Gregory, R. I.; Yan, K. P.; Amuthan, G.; Chendrimada, T.; Doratotaj, B.; Cooch, N.; Shiekhattar, R. The Microprocessor complex mediates the genesis of microRNAs. Nature, 2004, 432(7014), 235-240.
27. Kim, V. N. MicroRNA biogenesis: Coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol., 2005, 6(5), 376-85.
28. Li, M.; Marin-Muller, C.; Bharadwaj, U.; Chow, K. H.; Yao, Q.; Chen, C. MicroRNAs: Control and loss of control in human physiology and disease. World J. Surg., 2009, 33(4), 667-84.
29. Calin, G. A.; Dumitru, C. D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; Rassenti, L.; Kipps, T.; Negrini, M.; Bullrich, F.; Croce, C. M. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA, 2002, 99(24), 15524-15529.
30. Visone, R.; Croce, C. M., MiRNAs and cancer. Am. J. Pathol., 2009, 174(4), 1131-1138.
31. Hatley, M. E.; Patrick, D. M.; Garcia, M. R.; Richardson, J. A.; Bassel-Duby, R.; van Rooij, E.; Olson, E. N. Modulation of K-Rasdependent lung tumorigenesis by MicroRNA-21. Cancer Cell, 2010, 18(3), 282-93.
32. Johnson, S. M.; Grosshans, H.; Shingara, J.; Byrom, M.; Jarvis, R.; Cheng, A.; Labourier, E.; Reinert, K. L.; Brown, D.; Slack, F. J. RAS is regulated by the let-7 MicroRNA family. Cell, 2005, 120(5), 635-647.
33. Yanaihara, N.; Caplen, N.; Bowman, E.; Seike, M.; Kumamoto, K.; Yi, M.; Stephens, R. M.; Okamoto, A.; Yokota, J.; Tanaka, T.; Calin, G. A.; Liu, C. G.; Croce, C. M.; Harris, C. C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 2006, 9(3), 189-98.
34. Yu, S. L.; Chen, H. Y.; Chang, G. C.; Chen, C. Y.; Chen, H. W.; Singh, S.; Cheng, C. L.; Yu, C. J.; Lee, Y. C.; Chen, H. S.; Su, T. J.; Chiang, C. C.; Li, H. N.; Hong, Q. S.; Su, H. Y.; Chen, C. C.; Chen, W. J.; Liu, C. C.; Chan, W. K.; Li, K. C.; Chen, J. J.; Yang, P. C. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell, 2008, 13(1), 48-57.
35. Broxterman, H. J.; Gotink, K. J.; Verheul, H. M. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist. Updat., 2009, 12(4-5), 114-126.
36. Blower, P. E.; Chung, J. H.; Verducci, J. S.; Lin, S.; Park, J. K.; Dai, Z.; Liu, C. G.; Schmittgen, T. D.; Reinhold, W. C.; Croce, C. M.; Weinstein, J. N.; Sadee, W. MicroRNAs modulate the chemosensitivity of tumor cells. Mol. Cancer Ther., 2008, 7(1), 1-9.
37. Wu, X.; Xiao, H. miRNAs modulate the drug response of tumor cells. Sci. China C Life Sci., 2009, 52(9), 797-801.
38. Bertino, J. R.; Banerjee, D.; Mishra, P. J. Pharmacogenomics of microRNA: a miRSNP towards individualized therapy. Pharmacogenomics, 2007, 8(12), 1625-1627.
39. Orom, U. A.; Kauppinen, S.; Lund, A. H. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene, 2006, 372, 137-41.
40. Hutvagner, G.; Simard, M. J.; Mello, C. C.; Zamore, P. D. Sequencespecific inhibition of small RNA function. PLoS Biol., 2004, 2(4), E98.
41. Meister, G.; Landthaler, M.; Dorsett, Y.; Tuschl, T. Sequencespecific inhibition of microRNA-and siRNA-induced RNA silencing. RNA, 2004, 10(3), 544-50.
42. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K. G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with 'antagomirs'. Nature, 2005, 438(7068), 685-9.
43. Zheng, T.; Wang, J.; Chen, X.; Liu, L. Role of microRNA in anticancer drug resistance. Int. J. Cancer, 2010, 126(1), 2-10.
44. Wellner, U.; Schubert, J.; Burk, U. C.; Schmalhofer, O.; Zhu, F.; Sonntag, A.; Waldvogel, B.; Vannier, C.; Darling, D.; zur Hausen, A.; Brunton, V. G.; Morton, J.; Sansom, O.; Schuler, J.; Stemmler, M. P.; Herzberger, C.; Hopt, U.; Keck, T.; Brabletz, S.; Brabletz, T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol., 2009, 11(12), 1487-1495.
45. Shimono, Y.; Zabala, M.; Cho, R. W.; Lobo, N.; Dalerba, P.; Qian, D.; Diehn, M.; Liu, H.; Panula, S. P.; Chiao, E.; Dirbas, F. M.; Somlo, G.; Pera, R. A.; Lao, K.; Clarke, M. F. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell, 2009, 138(3), 592-603.
46. Peter, M. E. Regulating cancer stem cells the miR way. Cell Stem Cell, 2010, 6(1), 4-6.
47. Wang, Z.; Li, Y.; Ahmad, A.; Azmi, A. S.; Kong, D.; Banerjee, S.; Sarkar, F. H. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist. Updat., 2010, 13(4-5), 109-118.
48. Johnson, C. D.; Esquela-Kerscher, A.; Stefani, G.; Byrom, M.; Kelnar, K.; Ovcharenko, D.; Wilson, M.; Wang, X.; Shelton, J.; Shingara, J.; Chin, L.; Brown, D.; Slack, F. J. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res., 2007, 67(16), 7713-7722.
49. Fanale, D.; Caruso, S.; Bazan, V.; Bronte, G.; Di Piazza, F.; Rolfo, C.; Li Muli, M.; Cicero, G.; Russo, A. MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets. J. Carcinogenes. Mutagenes., 2013, 04(01).
50. Tsang, W. P.; Kwok, T. T. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J. Nutr. Biochem., 2010, 21(2), 140-146.
51. Sun, M.; Estrov, Z.; Ji, Y.; Coombes, K. R.; Harris, D. H.; Kurzrock, R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer Ther., 2008, 7(3), 464-473.
52. Melkamu, T.; Zhang, X.; Tan, J.; Zeng, Y.; Kassie, F. Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis, 2010, 31(2), 252-258.
53. Li, Y.; Kong, D.; Wang, Z.; Sarkar, F. H. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm. Res., 2010, 27(6), 1027-1041.
54. Sarkar, F. H.; Li, Y.; Wang, Z.; Kong, D.; Ali, S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist. Updat., 2010, 13(3), 57-66.
55. Buscaglia, L. E.; Li, Y. Apoptosis and the target genes of microRNA-21. Chin. J. Cancer, 2011, 30(6), 371-380.
56. Park, S. M.; Peter, M. E. microRNAs and death receptors. Cytokine Growth Factor Rev., 2008, 19(3-4), 303-311.
57. Schulze-Bergkamen, H.; Krammer, P. H. Apoptosis in cancer-implications for therapy. Semin. Oncol., 2004, 31(1), 90-119.
58. Kanakkanthara, A.; Miller, J. H. MicroRNAs: Novel mediators of resistance to microtubule-targeting agents. Cancer Treatment Rev., 2013, 39(2), 161-170.
59. Di Cristofano, A.; Pandolfi, P. P. The multiple roles of PTEN in tumor suppression. Cell, 2000, 100(4), 387-390.
60. Li, C.; Hashimi, S. M.; Good, D. A.; Cao, S.; Duan, W.; Plummer, P. N.; Mellick, A. S.; Wei, M. Q. Apoptosis and microRNA aberrations in cancer. Clin. Exp. Pharmacol. Physiol., 2012, 39(8), 739-746.
61. Bussing, I.; Slack, F. J.; Grosshans, H. let-7 microRNAs in development, stem cells and cancer. Trends Mol. Med., 2008, 14(9), 400-409.
62. Yvon, A. M.; Wadsworth, P.; Jordan, M. A. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell, 1999, 10(4), 947-959.
63. Wang, T. H.; Wang, H. S.; Soong, Y. K. Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together. Cancer, 2000, 88(11), 2619-2628.
64. Yu, H. Regulation of APC-Cdc20 by the spindle checkpoint. Curr. Opin. Cell Biol., 2002, 14(6), 706-714.
65. Rui, W.; Bing, F.; Hai-Zhu, S.; Wei, D.; Long-Bang, C. Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J. Cell Mol. Med., 2010, 14(1-2), 206-214.
66. Feng, B.; Wang, R.; Song, H. Z.; Chen, L. B. MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer, 2012, 118(13), 3365-3376.
67. Feng, S.; Cong, S.; Zhang, X.; Bao, X.; Wang, W.; Li, H.; Wang, Z.; Wang, G.; Xu, J.; Du, B.; Qu, D.; Xiong, W.; Yin, M.; Ren, X.; Wang, F.; He, J.; Zhang, B. MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. Nucleic Acids Res., 2011, 39(15), 6669-6678.
68. Holleman, A.; Chung, I.; Olsen, R. R.; Kwak, B.; Mizokami, A.; Saijo, N.; Parissenti, A.; Duan, Z.; Voest, E. E.; Zetter, B. R. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene, 2011, 30(43), 4386-4398.
69. Catuogno, S.; Cerchia, L.; Romano, G.; Pognonec, P.; Condorelli, G.; de Franciscis, V. miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene, 2013, 32(3), 341-351.
70. Du, L.; Subauste, M. C.; DeSevo, C.; Zhao, Z.; Baker, M.; Borkowski, R.; Schageman, J. J.; Greer, R.; Yang, C. R.; Suraokar, M.; Wistuba, II; Gazdar, A. F.; Minna, J. D.; Pertsemlidis, A. miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One, 2012, 7(6), e39167.
71. Klampfer, L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr. Cancer Drug Targets, 2006, 6(2), 107-121.
72. Galluzzi, L.; Morselli, E.; Vitale, I.; Kepp, O.; Senovilla, L.; Criollo, A.; Servant, N.; Paccard, C.; Hupe, P.; Robert, T.; Ripoche, H.; Lazar, V.; Harel-Bellan, A.; Dessen, P.; Barillot, E.; Kroemer, G. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res., 2010, 70(5), 1793-1803.
73. Zhang, S.; Zhang, C.; Li, Y.; Wang, P.; Yue, Z.; Xie, S. miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway. Biomed. Pharmacother., 2011, 65(6), 436-442.
74. Zhu, W.; Shan, X.; Wang, T.; Shu, Y.; Liu, P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int. J. Cancer, 2010, 127(11), 2520-2529.
75. Bian, H. B.; Pan, X.; Yang, J. S.; Wang, Z. X.; De, W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J. Exp. Clin. Cancer Res., 2011, 30, 20.
76. Zhu, W.; Zhu, D.; Lu, S.; Wang, T.; Wang, J.; Jiang, B.; Shu, Y.; Liu, P. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med. Oncol., 2012, 29(1), 384-391.
77. Zhu, W.; Xu, H.; Zhu, D.; Zhi, H.; Wang, T.; Wang, J.; Jiang, B.; Shu, Y.; Liu, P. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother. Pharmacol., 2012, 69(3), 723-731.
78. Gao, W.; Lu, X.; Liu, L.; Xu, J.; Feng, D.; Shu, Y. MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol. Ther., 2012, 13(5), 330-340.
79. Schaefer, U.; Voloshanenko, O.; Willen, D.; Walczak, H. TRAIL: a multifunctional cytokine. Front Biosci., 2007, 12, 3813-3824.
80. Xie, Y.; Tobin, L. A.; Camps, J.; Wangsa, D.; Yang, J.; Rao, M.; Witasp, E.; Awad, K. S.; Yoo, N.; Ried, T.; Kwong, K. F. MicroRNA-24 regulates XIAP to reduce the apoptosis threshold in cancer cells. Oncogene, 2013, 32(19), 2442-2451.
81. Garofalo, M.; Quintavalle, C.; Di Leva, G.; Zanca, C.; Romano, G.; Taccioli, C.; Liu, C. G.; Croce, C. M.; Condorelli, G. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene, 2008, 27(27), 3845-3855.
82. Benedettini, E.; Sholl, L. M.; Peyton, M.; Reilly, J.; Ware, C.; Davis, L.; Vena, N.; Bailey, D.; Yeap, B. Y.; Fiorentino, M.; Ligon, A. H.; Pan, B. S.; Richon, V.; Minna, J. D.; Gazdar, A. F.; Draetta, G.; Bosari, S.; Chirieac, L. R.; Lutterbach, B.; Loda, M. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am. J. Pathol., 2010, 177(1), 415-423.
83. Garofalo, M.; Romano, G.; Di Leva, G.; Nuovo, G.; Jeon, Y. J.; Ngankeu, A.; Sun, J.; Lovat, F.; Alder, H.; Condorelli, G.; Engelman, J. A.; Ono, M.; Rho, J. K.; Cascione, L.; Volinia, S.; Nephew, K. P.; Croce, C. M. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat. Med., 2012, 18(1), 74-82.
84. Acunzo, M.; Visone, R.; Romano, G.; Veronese, A.; Lovat, F.; Palmieri, D.; Bottoni, A.; Garofalo, M.; Gasparini, P.; Condorelli, G.; Chiariello, M.; Croce, C. M. miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene, 2012, 31(5), 634-642.
85. Nasser, M. W.; Datta, J.; Nuovo, G.; Kutay, H.; Motiwala, T.; Majumder, S.; Wang, B.; Suster, S.; Jacob, S. T.; Ghoshal, K. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J. Biol. Chem., 2008, 283(48), 33394-3405.
86. Incoronato, M.; Garofalo, M.; Urso, L.; Romano, G.; Quintavalle, C.; Zanca, C.; Iaboni, M.; Nuovo, G.; Croce, C. M.; Condorelli, G. miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res., 2010, 70(9), 3638-3646.
87. Donzelli, S.; Fontemaggi, G.; Fazi, F.; Di Agostino, S.; Padula, F.; Biagioni, F.; Muti, P.; Strano, S.; Blandino, G. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ., 2012, 19(6), 1038-1048.
88. Hodzic, J.; Giovannetti, E.; Diosdado, B.; Adema, A. D.; Peters, G. J. Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells. Nucleosides Nucleotides Nucleic Acids, 2011, 30(12), 1214-1222.
89. Lee, K. H.; Chen, Y. L.; Yeh, S. D.; Hsiao, M.; Lin, J. T.; Goan, Y. G.; Lu, P. J. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene, 2009, 28(38), 3360-3370.
90. Sharma, N.; Timmers, C.; Trikha, P.; Saavedra, H. I.; Obery, A.; Leone, G. Control of the p53-p21CIP1 Axis by E2f1, E2f2, and E2f3 is essential for G1/S progression and cellular transformation. J. Biol. Chem., 2006, 281(47), 36124-36131.
91. Wu, L.; Timmers, C.; Maiti, B.; Saavedra, H. I.; Sang, L.; Chong, G. T.; Nuckolls, F.; Giangrande, P.; Wright, F. A.; Field, S. J.; Greenberg, M. E.; Orkin, S.; Nevins, J. R.; Robinson, M. L.; Leone, G. The E2F1-3 transcription factors are essential for cellular proliferation. Nature, 2001, 414(6862), 457-462.
92. Cooper, C. S.; Nicholson, A. G.; Foster, C.; Dodson, A.; Edwards, S.; Fletcher, A.; Roe, T.; Clark, J.; Joshi, A.; Norman, A.; Feber, A.; Lin, D.; Gao, Y.; Shipley, J.; Cheng, S. J. Nuclear overexpression of the E2F3 transcription factor in human lung cancer. Lung Cancer, 2006, 54(2), 155-162.
93. Feng, B.; Wang, R.; Chen, L. B. MiR-100 resensitizes docetaxelresistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett., 2012, 317(2), 184-191.
94. Toyoshima-Morimoto, F.; Taniguchi, E.; Nishida, E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep., 2002, 3(4), 341-348.
95. Toyoshima-Morimoto, F.; Taniguchi, E.; Shinya, N.; Iwamatsu, A.; Nishida, E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature, 2001, 410(6825), 215-220.
96. Wang, Q.; Zhong, M.; Liu, W.; Li, J.; Huang, J.; Zheng, L. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp. Lung Res., 2011, 37(7), 427-434.
97. Zhang, X.; Zhu, J.; Xing, R.; Tie, Y.; Fu, H.; Zheng, X.; Yu, B. miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. Lung Cancer, 2012, 77(3), 488-494.
98. Takezawa, K.; Okamoto, I.; Tanizaki, J.; Kuwata, K.; Yamaguchi, H.; Fukuoka, M.; Nishio, K.; Nakagawa, K. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthasetargeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol. Cancer Ther., 2010, 9(6), 1647-1656.
99. Engelman, J. A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J. O.; Lindeman, N.; Gale, C. M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A. J.; Rogers, A. M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B. E.; Cantley, L. C.; Janne, P. A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007, 316(5827), 1039-1043.
100. Rai, K.; Takigawa, N.; Ito, S.; Kashihara, H.; Ichihara, E.; Yasuda, T.; Shimizu, K.; Tanimoto, M.; Kiura, K. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol. Cancer Ther., 2011, 10(9), 1720-1727.
101. Weiss, G. J.; Nelson, K. M.; Edwards, D. K.; Boisvert, S. P.; Sima, C. MicroRNA biomarkers associated with vandetanib, sunitinib, and/or erlotinib resistance. J. Thorac. Oncol., 2010, 5(6), S240-S241.
102. Nelson, K.; Sima, C.; Edwards, D. K.; Weiss, G. J. microRNA biomarkers associated with sunitinib-resistance in non-small cell lung cancer. Cancer Res., 2010, 70(8).
103. Allen, K. E.; Weiss, G. J. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol. Cancer Ther., 2010, 9(12), 3126-3136.
104. Wang, Y. S.; Wang, Y. H.; Xia, H. P.; Zhou, S. W.; Schmid-Bindert, G.; Zhou, C. C. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac. J. Cancer Prev., 2012, 13(1), 255-260.
105. Donnem, T.; Lonvik, K.; Eklo, K.; Berg, T.; Sorbye, S. W.; Al-Shibli, K.; Al-Saad, S.; Andersen, S.; Stenvold, H.; Bremnes, R. M.; Busund, L. T. Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer, 2011, 117(14), 3193-3200.
106. Zhong, M.; Ma, X.; Sun, C.; Chen, L. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. Chem. Biol. Interact., 2010, 184(3), 431-438.
107. Bryant, J. L.; Britson, J.; Balko, J. M.; Willian, M.; Timmons, R.; Frolov, A.; Black, E. P. A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Br. J. Cancer, 2012, 106(1), 148-156.
108. Weiss, G. J.; Bemis, L. T.; Nakajima, E.; Sugita, M.; Birks, D. K.; Robinson, W. A.; Varella-Garcia, M.; Bunn, P. A., Jr.; Haney, J.; Helfrich, B. A.; Kato, H.; Hirsch, F. R.; Franklin, W. A. EGFR regulation by microRNA in lung cancer: Correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann. Oncol., 2008, 19(6), 1053-1059.
109. Seike, M.; Goto, A.; Okano, T.; Bowman, E. D.; Schetter, A. J.; Horikawa, I.; Mathe, E. A.; Jen, J.; Yang, P.; Sugimura, H.; Gemma, A.; Kudoh, S.; Croce, C. M.; Harris, C. C. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in neversmokers. Proc. Natl. Acad. Sci. USA., 2009, 106(29), 12085-12090.